Elevated plasma prostaglandins and acetylated histone in monocytes in Type 1 diabetes patients: Short Report

Diabetic Medicine

Volumn 26, Issue 2, 2009, Pages 182-186

  Chen, S S H ^a   Jenkins, A J ^b   Majewski, H ^a  

^a RMIT UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Cyclooxygenase; Histone acetylation; Inflammation; Prostaglandins; Type 1 diabetes

Indexed keywords

CYCLOOXYGENASE 2; HISTONE; HISTONE H4; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; THROMBOXANE B2;

ACETYLATION; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE PREDISPOSITION; ENZYME IMMUNOASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MONOCYTE; PROSTAGLANDIN BLOOD LEVEL; PROSTAGLANDIN SYNTHESIS; UPREGULATION;

ACETYLATION; ADULT; AUSTRALIA; CROSS-SECTIONAL STUDIES; CYCLOOXYGENASE 2; DIABETES MELLITUS, TYPE 1; FEMALE; HISTONES; HUMANS; MALE; MONOCYTES; PLASMA; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS E; THROMBOXANE B2; UP-REGULATION;

EID: 60049100698     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2008.02658.x     Document Type: Article

References (20)

1. Lechleitner M, Koch T, Herold M, Dzien A, Hoppichler F. Tumour necrosis factor-alpha plasma level in patients with Type 1 diabetes mellitus and its association with glycaemic control and cardiovascular risk factors. J Intern Med 2000 248 : 67 76.
2. Jenkins AJ, Rothen M, Klein RL, Moller K, Eldridge L, Zheng D et al. Cross-sectional associations of C-reactive protein with vascular risk factors and vascular complications in the DCCT/EDIC cohort. J Diabetes Complications 2008 22 : 153 163.
3. Wohlim M, Helmersson J, Sundstrom J, Arnlov J, Vessby B, Larsson A et al. Both cyclooxygenase- and cytokine-mediated inflammation are associated with carotid intima-media thickness. Cytokine 2007 38 : 130 136.
4. 2-dependent plaque instability. Circulation 2001 104 : 921 927.
5. Samuelsson B, Morgenstern R, Jakobsson PJ. Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol Rev 2007 59 : 207 224.
6. Shanmugam N, Gaw Gonzalo IT, Natarajan R. Molecular mechanisms of high glucose-induced cyclooxygenase-2 expression in monocytes. Diabetes 2004 53 : 795 802.
7. Litherland SA, She JX, Schatz D, Fuller K, Hutson AD, Peng RH et al. Aberrant monocyte prostaglandin synthase 2 (PGS2) expression in Type 1 diabetes before and after disease onset. Pediatr Diabetes 2003 4 : 10 18.
8. 2 secretion from diabetic rat retinas. Eur J Pharmacol 2004 498 : 275 278.
9. 2 in juvenile-onset diabetes determined by high-pressure liquid chromatography and radio-immunoassay. Prostaglandins Leukot Med 1986 22 : 335 348.
10. Chase HP, Williams RL, Dupont J. Increased prostaglandin synthesis in childhood diabetes mellitus. J Pediatr 1979 94 : 185 189.
11. Arisaka M, Arisaka O, Yamashiro Y. Fatty acid and prostaglandin metabolism in children with diabetes mellitus. II The effect of evening primrose oil supplementation on serum fatty acid and plasma prostaglandin levels. Prostaglandins Leukot Essent Fatty Acids 1991 43 : 197 201.
12. Kang Y-J, Mbonye UR, DeLong CJ, Wada M, Smith WL. Regulation of intracellular cyclooxygenase levels by gene transcription and protein degradation. Lipid Res 2007 46 : 108 125.
13. Miao F, Gonzalo IG, Lanting L, Natarajan R. In vivo chromatin remodeling events leading to inflammatory gene transcription under diabetic conditions. J Biol Chem 2004 279 : 18091 18097.
14. 2 in monocytes stimulated in vitro by Chlamydia trachomatis, Chlamydophila pneumoniae and Mycoplasma fermentans. Microbial Pathogenesis 2004 37 : 155 161.
15. Beyan H, Goodier MR, Nawroly NS, Hawa MI, Bustin SA, Ogunkolade WB et al. Altered monocyte cyclooxygenase response to lipopolysaccharide in Type 1 diabetes. Diabetes 2006 55 : 3439 3445.
16. Cipollone F, Iezzi A, Fazia M. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation 2003 108 : 1070 1077.
17. Park GY, Joo M, Pedchenko T, Blackwell TS, Christman JW. Regulation of macrophage cyclooxygenase-2 gene expression by modifications of histone H3. Am J Physiol Lung Cell Mol Physiol 2004 286 : L956 962.
18. Wang J, Mahmud SA, Bitterman PB, Huo Y, Slungaard A. Histone deacetylase inhibitors suppress TF-κB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes. J Biol Chem 2007 282 : 28408 28418.
19. Inoue K, Kobayashi M, Yano K, Miura M, Izumi A, Mataki C et al. Histone deacetylase inhibitor reduces monocyte adhesion to endothelium through the suppression of vascular cell adhesion molecule-1 expression. Arterioscler Throm Vasc Biol 2006 26 : 2652 2659.
20. Lee HB, Noh H, Seo JY, Yu MR, Ha H. Histone deacetylase inhibitors: a novel class of therapeutic agents in diabetic nephropathy. Kidney Int Suppl 2007 106 : S61 66.